About Avadel Pharmaceuticals plc - Ordinary Share (AVDL)
Avadel Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for patients with sleep disorders, specifically targeting conditions like narcolepsy and obstructive sleep apnea. The company leverages its proprietary drug delivery technology to create novel formulations designed to improve patient outcomes and enhance medication adherence. Avadel aims to address unmet medical needs through its advanced therapies while also pursuing strategic partnerships and collaborations to expand its product offerings and reach in the pharmaceutical market. Read More
Avadel reviews Lundbeck's unsolicited $23 offer while maintaining its agreement with Alkermes as its board evaluates whether the new proposal could be superior.
Avadel’s board of directors is of the opinion that the fresh proposal would reasonably be expected to be considered superior to the company’s existing agreement with Alkermes.
Avadel Pharmaceuticals (AVDL) meets the Mark Minervini Trend Template with a strong technical uptrend and accelerating earnings and sales growth momentum.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avadel Pharmaceuticals plc (NasdaqGM: AVDL) to Alkermes plc (NasdaqGS: ALKS). Under the terms of the proposed transaction, shareholders of Avadel will receive $18.50 per share, plus a non-transferable contingent value right entitling holders to a potential additional cash payment of $1.50 per share, contingent upon final FDA approval of LUMRYZ™ for the treatment of idiopathic hypersomnia in adults by the end of 2028. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.
DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for a staggering $2.1 billion. The news sent Avadel's stock price soaring in premarket trading, reflecting a significant premium offered to its investors.
BALA CYNWYD, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avadel Pharmaceuticals plc (NASDAQ: AVDL) to Alkermes plc is fair to Avadel shareholders. Under the terms of the proposed transaction, Avadel shareholders will receive $18.50 per share, plus a non-transferable contingent value right entitling holders to a potential additional cash payment of $1.50 per share, contingent upon final FDA approval of LUMRYZ™ for the treatment of idiopathic hypersomnia in adults by the end of 2028.
